var docs;if (!docs) docs =[]; docs["38"]={"3800":"<p><b>Title</b> Zidovudine / Atovaquone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Atovaquone may increase the serum concentration of Zidovudine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of zidovudine (200 mg every 8 hours) was increased 31% in 14 HIV-infected subjects when coadministered with atovaquone (750 mg every 12 hours) for 12 days.<sup>1</sup> There were no changes in atovaquone pharmacokinetics. No evidence of untoward clinical effects was identified. Atovaquone appeared to inhibit the glucuronidation of zidovudine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee BL, Tauber MG, Sadler B, et al, “Atovaquone Inhibits the Glucuronidation and Increases the Plasma Concentrations of Zidovudine,” <i>Clin Pharmacol Ther</i>, 1996, 59(1):14-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8549029\">[PubMed 8549029]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3801":"<p><b>Title</b> LamoTRIgine / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may increase the metabolism of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced serum concentrations and effects of lamotrigine if rifampin is initiated/dose increased, and increased concentrations/effects if rifampin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of lamotrigine (25 mg) was decreased more than 40% in ten normal subjects when administered following a 5-day course of rifampin (600 mg daily).<sup>1</sup> Clearance was increased, as was the amount of lamotrigine excreted as a glucuronide metabolite. Rifampin induces uridine 5'-diphosphate-glucuronyl transferase (UDPGT), the enzyme responsible for the glucuronidation of lamotrigine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ebert U, Thong NQ, Oertel R, et al, “Effects of Rifampicin and Cimetidine on Pharmacokinetics and Pharmacodynamics of Lamotrigine in Healthy Subjects,” <i>Eur J Clin Pharmacol</i>, 2000, 56(4):299-304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10954343\">[PubMed 10954343]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3802":"<p><b>Title</b> Melphalan / Nalidixic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nalidixic Acid may enhance the adverse/toxic effect of Melphalan. Necrotic enterocolitis has been reported in pediatric patients. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk/severity of gastrointestinal side effects during concomitant use. Severe hemorrhagic necrotic enterocolitis has been reported with this combination.</p> \n<p><b>Discussion</b> According to the melphalan labeling, the incidence of severe hemorrhagic necrotic enterocolitis in pediatric patients is increased during concomitant treatment with nalidixic acid and IV melphalan.<sup>1,2</sup> The reason for this is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Alkeran (melphalan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2011.</p>\n<p>2. Evomela (melphalan) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals Inc.; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3808":"<p><b>Title</b> Thiazolidinediones / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may decrease the metabolism of Thiazolidinediones. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of thiazolidinediones if trimethoprim is initiated/dose increased, and decreased effects if trimethoprim is discontinued/dose decreased.</p>\n<div>\n <p><b>Thiazolidinediones Interacting Members</b> Lobeglitazone, Pioglitazone, Rosiglitazone*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of rosiglitazone (4 mg single dose) was increased 37% in 10 normal subjects when administered on day 3 of a 4-day course of trimethoprim (160 mg twice daily).<sup>1</sup> The formation of N-desmethylrosiglitazone was decreased. Trimethoprim appears to inhibit the CYP2C8-mediated metabolism of rosiglitazone. Pioglitazone may be similarly affected (although likely to a lesser degree as it is also metabolized via CYP3A4).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Backman JT, and Neuvonen PJ, “Effects of Trimethoprim and Rifampin on the Pharmacokinetics of the Cytochrome P450 2C8 Substrate Rosiglitazone,” <i>Clin Pharmacol Ther</i>, 2004, 76(3):239-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15371985\">[PubMed 15371985]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3809":"<p><b>Title</b> Apomorphine / Antiemetics (5HT3 Antagonists)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The manufacturer of apomorphine labels the concomitant use of apomorphine and 5HT3 antagonists as contraindicated.<sup>1</sup> If used concomitantly, monitor for evidence of hypotension.</p>\n<div>\n <p><b>Antiemetics (5HT3 Antagonists) Interacting Members</b> Alosetron, Dolasetron, Granisetron, Ondansetron*, Palonosetron, Ramosetron, Tropisetron</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The manufacturer of apomorphine references “reports of profound hypotension and loss of consciousness” during concomitant administration with ondansetron.<sup>1</sup> As a result, combined use of apomorphine with all 5HT3 antagonists is contraindicated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Apokyn (apomorphine). Morristown, NJ: Vernalis Pharmaceuticals, Inc., June 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3812":"<p><b>Title</b> Imatinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may increase the metabolism of Imatinib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The concomitant use of St Johns wort and imatinib should be avoided, if possible. Monitor for decreased effects of imatinib during concomitant use. No specific recommendations for increased doses of imatinib during concomitant use are available.</p> \n<p><b>Discussion</b> The AUC of imatinib (400 mg single dose) was decreased 32% in 10 normal subjects when administered following a 2-week course of St Johns wort (300 mg 3 times daily).<sup>1</sup> As an effective CYP3A4 inducer, St Johns wort likely induced the CYP3A4-mediated metabolism of imatinib. Reduced clinical efficacy is possible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Smith P, “The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate,” <i>Pharmacother</i>, 2004, 24(11):1508-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15537555\">[PubMed 15537555]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3816":"<p><b>Title</b> Dofetilide / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium and magnesium more closely when dofetilide is combined with loop diuretics. Electrolyte replacements will likely be required to maintain potassium and magnesium serum concentrations within the normal range prior to, and during, the administration of dofetilide. Subtherapeutic electrolyte concentrations may result in QTc prolongation or torsade de pointe.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> Dofetilide-associated (500 mcg twice daily) QTc interval prolongation was nearly doubled in patients during coadministration with hydrochlorothiazide (50 mg daily).<sup>1</sup> Increased dofetilide exposure accounted for some of this effect; however, diuretic-induced reductions in serum potassium (and the associated increases in dofetilide effects) offers an additional reason for these observations. <br><br>Dofetilide prescribing information states that hypokalemia or hypomagnesemia may occur with administration of potassium-depleting diuretics (ie, loop diuretics), increasing the potential for torsade de pointes.<sup>1</sup> Potassium levels should be within the normal range prior to, and during, the administration of dofetilide.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3817":"<p><b>Title</b> Dofetilide / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Dofetilide. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The concomitant use of hydrochlorothiazide and dofetilide is contraindicated by the manufacturer of dofetilide. Although hydrochlorothiazide is specifically cited in this contraindication, the risk likely extends to all thiazide and thiazide-like diuretics and may be even greater with chlorthalidone or bendroflumethiazide. Monitor for increased risk of QTc-prolongation and associated ventricular arrythmias during concomitant use of dofetilide and thiazide diuretics.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide*, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The manufacturer of dofetilide specifically contraindicates the use of hydrochlorothiazide.<sup>1</sup> The AUC of dofetilide (500 mcg twice daily) was increased approximately 30% in patients receiving hydrochlorothiazide (50 mg) either alone or in combination with triamterene (100 mg) daily.<sup>1</sup> The increase in dofetilide-associated QTc interval prolongation was nearly doubled during concomitant hydrochlorothiazide administration. Increased dofetilide exposure, combined with diuretic-induced reductions in serum potassium (and the associated increases in dofetilide effects) likely explain these observations. <br><br>Although the dofetilide prescribing information specifically cites hydrochlorothiazide, this interaction likely also applies to other thiazide and thiazide-like diuretics. Chlorthalidone use was associated with a greater risk of hospitalizations due to low potassium (adjusted HR=3.06) than hydrochlorothiazide use in an observational cohort study of elderly patients recently started on chlorthalidone or hydrochlorothiazide.<sup>2</sup> The clinical significance of these results should be interpreted with caution, as the study has some notable limitations in addition to those inherent with this general design including that all patients were over 66 years of age, and that many had been hospitalized in the past (perhaps making them more prone to hospitalization for electrolyte abnormalities). Several other cohort studies and meta-analyses have also reported greater potassium-lowering effects with chlorthalidone as compared to hydrochlorothiazide, though the differences tended to be of only small or modest magnitude and of uncertain clinical significance.<sup>3,4,5,6,7</sup> In contrast, one retrospective study of 40 patients who had been changed from hydrochlorothiazide to chlorthalidone noted no significant difference in potassium.<sup>6</sup><br><br>One meta-analysis also attributed a greater potassium-lowering (and blood pressure-lowering) effect with bendroflumethiazide, ranking bendroflumethiazide as having the greatest effect followed by chlorthalidone and then by hydrochlorothiazide.<sup>4</sup> It is noteworthy that only one of the included studies evaluated bendroflumethiazide, and only 3 evaluated chlorthalidone, compared to the 26 included studies that evaluated hydrochlorothiazide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tikosyn (dofetilide). New York, NY: Pfizer, March 2004.</p>\n<p>2. Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. <i>Ann Int Med</i>. 2013; 158(6):447-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23552325\">[PubMed 23552325]</a></p>\n<p>3. Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. <i>Am J Hypertens</i>. 2010;23:440-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20111008\">[PubMed 20111008]</a></p>\n<p>4. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflume-thiazide on blood pressure, serum potassium, and urate. <i>Hypertension</i>. 2012;59:1104-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22547443\">[PubMed 22547443]</a> </p>\n<p>5. Wolfgram DF, Gundu V, Astor BC, Jhagroo RA. Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones. <i>Urolithiasis</i>. 2013;41(4):315-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23660825\">[PubMed 23660825]</a></p>\n<p>6. Matthews KA, Brenner MJ, Brenner AC. Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. <i>Clin Ther</i>. 2013;35(9):1423-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23993697\">[PubMed 23993697]</a></p>\n<p>7. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. <i>Hypertension</i>. 2011;57(4):689-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383313\">[PubMed 21383313]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3818":"<p><b>Title</b> DOCEtaxel / Aprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Aprepitant does not appear to affect serum concentration of DOCEtaxel. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 cancer patients receiving docetaxel, the administration of aprepitant (125 mg single dose 1 hour prior to docetaxel infusion on day 1 and 80 mg daily on days 2 and 3) had no effect on docetaxel pharmacokinetics.<sup>1</sup> Similarly, no change in docetaxel pharmacokinetics was observed when aprepitant (125 mg single dose) was administered 3 hours prior to docetaxel infusion in 16 cancer patients.<sup>2</sup> Additionally, the prescribing information for aprepitant states that in a pharmacokinetic study, aprepitant had no effect on the pharmacokinetics of docetaxel.<sup>3</sup><br> <br>Although aprepitant is a moderate inhibitor of CYP3A4, an enzyme responsible for docetaxel metabolism, no additional monitoring or dose adjustments are required when these agents are combined.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. <i>Cancer Chemother Pharmacol</i>. 2005;55(6):609-616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15723220\">[PubMed 15723220]</a></p>\n<p>2. Kaneta T, Fujita K, Akiyama Y, et al. No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion. <i>Cancer Chemother Pharmacol</i>. 2014;74(3):539-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25053387\">[PubMed 25053387]</a></p>\n<p>3. Emend (aprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3822":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / AtorvaSTATin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> AtorvaSTATin may increase the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of ethinyl estradiol (as part of an estrogen-progestin combination oral contraceptive) was increased 19% in 12 female subjects when coadministered with atorvastatin.<sup>1</sup> The AUC of norethindrone was increased 28%. The clinical implications of these pharmacokinetic changes appear negligible. The mechanism of the observed changes is unknown.<br><br>Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yang BB, Siedlik PH, Smithers JA, et al, “Atorvastatin Pharmacokinetic Interactions With Other CYP3A4 Substrates: Erythromycin and Ethinyl Estradiol,” <i>Pharm Res</i>, 1996, 13(Sup 9):S437.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3824":"<p><b>Title</b> Solifenacin / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Hepatic Function</b>: Solifenacin use with itraconazole is considered contraindicated in patients with moderate to severe hepatic impairment.</p></li>\n <li><p><b>Renal Function</b>: Solifenacin use with itraconazole is considered contraindicated in patients with severe renal impairment.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The manufacturer recommends not exceeding 5 mg daily of solifenacin during concomitant therapy with ketoconazole, or other potent CYP3A4 enzyme inhibitors. Monitor for increased effects of solifenacin if an azole antifungal is initiated/dose increased, or decreased effects if an azole antifungal is discontinued/dose decreased. Itraconazole US prescribing information lists its use with solifenacin as contraindicated in patients with severe renal impairment or moderate to severe hepatic impairment.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n</div> \n<p><b>Discussion</b> The AUC of solifenacin (10 mg) was increased 2.7-fold in a study involving normal subjects when coadministered with ketoconazole (400 mg).<sup>1</sup> Ketoconzole, a strong CYP3A4 enzyme inhibitor, likely reduced solifenacin metabolism. Itraconazole US prescribing information lists its use with solifenacin as contraindicated in patients with severe renal impairment or moderate to severe hepatic impairment.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vesicare (solifenacin) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; October 2013.</p>\n<p>2. Sporanox (itraconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3826":"<p><b>Title</b> Natalizumab / Interferon Beta-1a</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Interferon Beta-1a may increase the serum concentration of Natalizumab. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The clearance of natalizumab (6 mg/kg single dose) was decreased 30% in multiple sclerosis patients receiving interferon beta-1a (30 mcg weely).<sup>1</sup> No changes in the effects of natalizumab were observed. The manufacturer notes that no change in dose of natalizumab is needed.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vollmer TL, Phillips JT, Goodman AD, et al, “An Open-Label Safety and Drug Interaction Study of Natalizumab (Antegren) in Combination with Interferon-beta (Avonex) in Patients with Multiple Sclerosis,” <i>Mult Scler</i>, 2004, 10(5):511-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15471366\">[PubMed 15471366]</a></p>\n<p>2. Tysabri [package insert]. Cambridge, MA: Biogen Idec Inc, 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3827":"<p><b>Title</b> Oxytocin / Dinoprostone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dinoprostone may enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of dinoprostone and oxytocin is not recommended. If used sequentially, monitor uterine activity closely. It is recommended to administer oxytocin at least 30 minutes after the removal of a dinoprostone vaginal insert and 6 to 12 hours after the application of dinoprostone gel.</p> \n<p><b>Discussion</b> In a clinical study, concurrent administration of intravaginal dinoprostone with oxytocin for labor induction in 250 females resulted in higher rates of cesarean section deliveries (16.8%)<br>compared with sequential administration of oxytocin 6 hours following intravaginal dinoprostone (6.8%).<sup>1</sup><br><br>In contrast, various clinical studies have shown improved labor induction results, or no significant changes or adverse events, following concurrent administration of dinoprostone and oxytocin.<sup>2,3,4,5</sup><br><br>Dinoprostone product labeling states that because dinoprostone may augment the activity of oxytocic agents (ie, oxytocin), their concomitant use is not recommended.<sup>6,7,8</sup> If they are used sequentially, uterine activity should be monitored closely, and oxytocin should be initiated at least 30 minutes after the removal of a dinoprostone vaginal insert and 6 to 12 hours after application of dinoprostone vaginal gel.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gungorduk K, Yildirim G, Gungorduk O, Ark C, Tekirdag I. Sustained-release dinoprostone vaginal pessary with concurrent high-dose oxytocin infusion compared to sustained-release dinoprostone vaginal pessary followed 6 hours later by high-dose oxytocin infusion for labor induction in women at term with unfavorable cervix: a randomized controlled trial. <i>Gynecol Obstet Invest</i>. 2011;71(1):32-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21160192\">[PubMed 21160192]</a></p>\n<p>2. Hennessey MH, Rayburn WF, Stewart JD, Liles EC. Pre-eclampsia and induction of labor: a randomized comparison of prostaglandin E2 as an intracervical gel, with oxytocin immediately, or as a sustained-release vaginal insert. <i>Am J Obstet Gynecol</i>. 1998;179(5):1204-1209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9822501\">[PubMed 9822501]</a></p>\n<p>3. Stewart JD, Rayburn WF, Farmer KC, Liles EM, Schipul AH Jr, Stanley JR. Effectiveness of prostaglandin E2 intracervical gel (Prepidil), with immediate oxytocin, versus vaginal insert (Cervidil) for induction of labor. <i>Am J Obstet Gynecol</i>. 1998;179(5):1175-1180. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9822496\">[PubMed 9822496]</a></p>\n<p>4. Christensen FC, Tehranifar M, Gonzalez JL, Qualls CR, Rappaport VJ, Rayburn WF. Randomized trial of concurrent oxytocin with a sustained-release dinoprostone vaginal insert for labor induction at term. <i>Am J Obstet Gynecol</i>. 2002;186(1):61-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11810086\">[PubMed 11810086]</a></p>\n<p>5. Bolnick JM, Velazquez MD, Gonzalez JL, Rappaport VJ, Mcllwain-Dunivan G, Rayburn WF. Randomized trial between two active labor management protocols in the presence of an unfavorable cervix. <i>Am J Obstet Gynecol</i>. 2004;190(1):124-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14749647\">[PubMed 14749647]</a></p>\n<p>6. Prepidil (dinoprostone) vaginal gel [prescribing information] New York, NY: Pfizer Inc; February 2010.</p>\n<p>7. Cervidil (dinoprostone) vaginal insert [prescribing information]. St. Louis, MO: Forest Laboratories Inc; April 2010.</p>\n<p>8. Prostin E2 (dinoprostone) intravenous solution [summary of product characteristics]. Sandwich, Kent, UK: Pfizer Limited; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3828":"<p><b>Title</b> Oxytocin / MiSOPROStol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> MiSOPROStol may enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The manufacturer of misoprostol recommends avoiding concomitant use with oxytocin. Misoprostol may augment oxytocic effects, particularly when given within 4 hours of oxytocin initiation.</p> \n<p><b>Discussion</b> The oxytocic activity of oxytocin may be augmented by agents used to promote cervical ripening (e.g., dinoprostone and misoprostol).<sup>1</sup> Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cytotec (misoprostol). New York, NY: Pfizer Inc, September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3829":"<p><b>Title</b> Alcohol (Ethyl) / Pimecrolimus</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pimecrolimus may enhance the dermatologic adverse effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Advise patients using topical pimecrolimus of the increased potential for experiencing facial flushing following the consumption of alcoholic beverages. Aspirin, as a prostaglandin inhibitor, may attenuate the effects if needed.</p> \n<p><b>Discussion</b> Case reports (some including rechallenge) and adverse effects reports from clinical trials describe the development of localized flushing (including redness and warm sensation) at the application sites of topical tacrolimus<sup>1,2,3,4,5</sup> and pimecrolimus<sup>2</sup> within 5-15 minutes of alcohol consumption. The overall incidence of “alcohol intolerance” (as it is described in the tacrolimus ointment package insert) is reported as 3.7-6.9%.<sup>1,5</sup> No mention of alcohol-related concerns or effects is mentioned in the pimecrolimus package insert.<sup>6</sup> The effects observed in the cited cases lasted approximately 1 hour. A mechanism for this observation is unclear. It has been postulated that aldehyde dehydrogenase inhibition by tacrolimus in the skin at the application site may lead to increase acetaldehyde concentrations and subsequent effects (mediated via either prostaglandins).<sup>2</sup> Aspirin administration has been noted to attenuate the effects in a couple of cases.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Soter NA, Fleischer AB Jr, Webster GF, et al, “Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Adult Patients: Part II, Safety,” <i>J Am Acad Dermatol</i>, 2001, 44(1 Suppl):S39-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11145794\">[PubMed 11145794]</a></p>\n<p>2. Ehst BD and Warshaw EM, “Alcohol-Induced Application Site Erythema After Topical Immunomodulator Use and Its Inhibition by Aspirin,” <i>Arch Dermatol</i>, 2004, 140(8):1014-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15313828\">[PubMed 15313828]</a></p>\n<p>3. Milingou M, Antille C, Sorg O, et al, “Alcohol Intolerance and Facial Flushing in Patients Treated With Topical Tacrolimus,” <i>Arch Dermatol</i>, 2004, 140(12):1542-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15611445\">[PubMed 15611445]</a></p>\n<p>4. Lubbe J and Milingou M, “Images in Clinical Medicine. Tacrolimus Ointment, Alcohol, and Facial Flushing,” <i>N Engl J Med</i>, 2004, 351(26):2740. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15616208\">[PubMed 15616208]</a></p>\n<p>5. Personal Communication. Eileen Jaracz, PharmD, Fujisawa Healthcare Inc Medical Information Department, Deerfield, IL. January 11, 2005.</p>\n<p>6. Elidel [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3830":"<p><b>Title</b> Indinavir / Ascorbic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ascorbic Acid may decrease the serum concentration of Indinavir. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of indinavir (800 mg every 8 hours) was decreased 14% in 7 healthy volunteers when administered on days 6-7 of a 7-day course of oral vitamin C (1 g daily).<sup>1</sup> The maximum concentration of indinavir was decreased 20%. No change in clearance or half-life occurred. Neither the clinical significance nor mechanism of these observations are known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Slain D, Amsden JR, Khakoo RA, Fisher MA, et al, “Effect of High-Dose Vitamin C on the Steady-State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers,” <i>Pharmacother</i>, 2005, 25(2):165-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767232\">[PubMed 15767232]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3831":"<p><b>Title</b> Zonisamide / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Zonisamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor zonisamide serum concentrations during concomitant therapy with phenytoin. Increased zonisamide doses may be necessary. Monitor for evidence of CNS depression.</p> \n<p><b>Discussion</b> The AUC of zonisamide is significantly decreased during concomitant administration of phenytoin.<sup>1</sup> In contrast, zonisamide does not affect phenytoin pharmacokinetics.<sup>1,2</sup> Phenytoin appears to increase the CYP3A4-mediated metabolism of zonisamide. Additive CNS depressant effects may be evident, too.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shinoda M, Akita M, Hasegawa M, et al, “The Necessity of Adjusting the Dosage of Zonisamide When Coadministered with Other Anti-epileptic Drugs,” <i>Biol Pharm Bull</i>, 1996, 19(8):1090-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8874824\">[PubMed 8874824]</a></p>\n<p>2. Levy RH, Ragueneau-Majlessi I, Garnett WR, et al, “Lack of a Clinically Significant Effect of Zonisamide on Phenytoin Steady-State Pharmacokinetics in Patients with Epilepsy,” <i>J Clin Pharmacol</i>, 2004, 44(11):1230-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15496640\">[PubMed 15496640]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3832":"<p><b>Title</b> Sertraline / Donepezil</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Donepezil does not appear to affect serum concentration of Sertraline. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> No clinically significant pharamacokinetic interaction was identified in 16 normal subjects during a 15-day course of concomitant administration of donepezil (5 mg daily) and sertraline (50 - 100 mg daily)<sup>1</sup> No unexpected adverse reactions were observed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nagy CF, Kumar D, Perdomo CA, et al, “Concurrent Administration of Donepezil HCl and Sertraline HCl in Healthy Volunteers: Assessment of Pharmacokinetic Changes and Safety Following Single and Multiple Oral Doses,” <i>Br J Clin Pharmacol</i>, 2004, 58(Suppl 1):25-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15496220\">[PubMed 15496220]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3834":"<p><b>Title</b> Fexofenadine / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Verapamil may increase the serum concentration of Fexofenadine. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased effects of fexofenadine if verapamil is initiated/dose increased, and decreased effects if verapamil is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of fexofenadine (120 mg single dose) increased 2.5-fold in 12 healthy subjects when administered following a 6-day course of verapamil (80 mg three times daily).<sup>1</sup> In another pharmacokinetic study of 12 healthy volunteers, the AUC of fexofenadine (60 mg single dose) increased 62% when coadministered with a single dose of verapamil (240 mg), increased 46% after a 10-day course of verapamil, but was unchanged after a 38-day course of verapamil.<sup>2</sup> In a final pharmacokinetic study of 13 healthy volunteers, when verapamil (80 mg three times daily for 6 days) was coadministered with fexofenadine (120 mg single dose), the AUC of S-fexofenadine increased 3.5-fold and the AUC of R-fexofenadine increased 2.2-fold.<sup>3</sup><br><br>The mechanism of this interaction is likely due to verapamil-mediated inhibition of P-glycoprotein, a transporter responsible for fexofenadine disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. <i>Clin Pharmacol Ther</i>. 2005;77(1):17-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15637527\">[PubMed 15637527]</a></p>\n<p>2. Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. <i>Clin Pharmacol Ther</i>. 2006;79(3):218-230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16513446\">[PubMed 16513446]</a>P</p>\n<p>3. Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. <i>Br J Clin Pharmacol</i>. 2009;67(5):535-540. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19552748\">[PubMed 19552748]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3835":"<p><b>Title</b> Fexofenadine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Cimetidine does not appear to affect serum concentration of Fexofenadine. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A 6-day course of cimetidine (800 mg daily) had no appreciable effect on the plasma concentrations of a single dose of fexofenadine (120 mg) in 12 normal subjects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yasui-Furukori N, Uno T, Sugawara K, et al, “Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 2005, 77(1):17-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15637527\">[PubMed 15637527]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3836":"<p><b>Title</b> Fexofenadine / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Probenecid may decrease the excretion of Fexofenadine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of fexofenadine (120 mg) was increased 1.5-fold in 12 normal subjects when administered following a 6-day course of probenecid (2000 mg).<sup>1</sup> Probenecid presumably inhibits the OAT-mediated renal transport of fexofenadine. The clinical significance of this effect is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yasui-Furukori N, Uno T, Sugawara K, et al, “Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 2005, 77(1):17-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15637527\">[PubMed 15637527]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3839":"<p><b>Title</b> Alosetron / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> FluvoxaMINE may decrease the metabolism of Alosetron. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of alosetron and fluvoxamine. This combination is listed as contraindicated in alosetron product labeling.</p> \n<p><b>Discussion</b> The AUC of alosetron (1 mg single dose) was increased 6-fold in 40 healthy female subjects when administered on the last day of a 16-day course of fluvoxamine (50 to 200 mg daily in escalating doses).<sup>1</sup> The half-life was increased approximately 3-fold.<sup>1</sup><br><br>Alosetron prescribing information states that because fluvoxamine can increase alosetron concentrations and the risk for adverse effects, the concomitant use of these agents is contraindicated.<sup>1</sup> <br><br>The mechanism of this interaction is due to fluvoxamine-mediated inhibition of CYP1A2, an enzyme responsible for alosetron metabolism. Fluvoxamine-mediated inhibition of CYP3A4 or CYP2C9 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lotronex (alosetron) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3840":"<p><b>Title</b> COMT Substrates / COMT Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> COMT Inhibitors may decrease the metabolism of COMT Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of exogenously administered COMT substrates if used concomitant with a COMT inhibitor.</p>\n<div>\n <p><b>COMT Inhibitors Interacting Members</b> Entacapone, Tolcapone</p>\n <p><b>COMT Substrates Interacting Members</b> Apomorphine, DOBUTamine, DOPamine, EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Isoproterenol, Methyldopa, Norepinephrine</p>\n</div> \n<p><b>Discussion</b> Epinephrine (1-12 mcg/min) or isoproterenol (0.5-2 mcg/min)-induced increases in heart rate were 48-79% higher in 5 normal subjects who received a single 400 mg dose of entacapone prior to the infusions.<sup>1</sup> No statistically different increases in blood pressure were noted. The manufacturer describes one case of ventricular tachycardia in a normal subject during concomitant treatment with epinephrine (via infusion) and oral entacapone.<sup>2</sup> The extent of clinical effects following the use of epinephrine as a vasoconstrictor (such as when combined with a local anesthetic) are unknown. Epinephrine is metabolized via catechol-O-methyltransferase (COMT), as well as other endogenous enzymes (eg, monoamine oxidase). COMT inhibitors will reduce the metabolism of COMT substrates resulting in increased concentrations/effects of the latter.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Illi A, Sundberg S, Ojala-Karlsson P, et al, “The Effect of Entacapone on the Disposition and Hemodynamic Effects of Intravenous Isoproterenol and Epinephrine,” <i>Clin Pharmacol Ther</i>, 1995, 58(2):221-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7648772\">[PubMed 7648772]</a></p>\n<p>2. Comtan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2000.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3841":"<p><b>Title</b> Monoamine Oxidase Inhibitors / COMT Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> COMT Inhibitors may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of COMT inhibitors and nonselective monoamine oxidase inhibitors (eg, isocarboxazid, phenelzine, tranylcypromine) should be avoided. Coadministration with selective MAOI (eg, moclobemide, selegiline (&lt;10 mg oral tablet/capsule or &lt;2.5 mg orally disintegrating tablet)) should be undertaken with caution. Monitor for increased catecholamine effects.</p>\n<div>\n <p><b>COMT Inhibitors Interacting Members</b> Entacapone*, Tolcapone</p>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide*, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) represent the two primary enzymes responsible for the metabolism of endogenous catecholamines. Combined use of inhibitors of these pathways could result in a marked increase in circulating catecholamines, and a resultant increase in effects.<sup>1</sup> Concomitant administration of entacapone (200 mg) and moclobemide, a selective MAO-A inhibitor, (150 mg) did not have any negative hemodynamic effects on 12 normal male subjects.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Comtan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2000.</p>\n<p>2. Illi A, Sundberg S, Ojala-Karlsson P, et al, “Simultaneous Inhibition of Catechol-O-methyltransferase and Monoamine Oxidase A: Effects on Hemodynamics and Catecholamine Metabolism in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 1996, 59(4):450-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8612391\">[PubMed 8612391]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3843":"<p><b>Title</b> Methotrexate / Folic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Folic Acid does not appear to alter the pharmacodynamic effect(s) of Methotrexate. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Several reports (prospective trials and clinician surveys) indicate that folic acid (up to 50 mg weekly) reduces the side effects, but not efficacy, of low-dose methotrexate used in the treatment of rheumatoid arthritis or psoriasis.<sup>1,2,3,4,5,6,7</sup> It also appears to reduce methotrexate induced increases in plasma homocysteine concentrations.<sup>8</sup> However, one clinical crossover study of 20 patients with psoriasis found a significant decrease in antipsoriatic effects of methotrexate (individualized doses) when given with folic acid (20 mg/week) compared to placebo.<sup>9</sup> <br><br>Methotrexate U.S. prescribing information warns that folic acid and its derivatives may decrease methotrexate responses.<sup>10</sup> Based on the data cited above, though, the clinical impact of administering folic acid with low-dose methotrexate appears to be predominantly beneficial in nature.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Morgan SL, Baggott JE, Vaughn WH, et al, “Supplementation with Folic Acid During Methotrexate Therapy for Rheumatoid Arthritis. A Double-Blind, Placebo-Controlled Trial,” <i>Ann Intern Med</i>, 1994, 121(11):833-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7978695\">[PubMed 7978695]</a></p>\n<p>2. Morgan SL, Baggott JE, Vaughn WH, et al, “The Effect of Folic Acid Supplementation on the Toxicity of Low-Dose Methotrexate in Patients with Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 1990, 33(1):9-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2405864\">[PubMed 2405864]</a></p>\n<p>3. Kirby B, Lyon CC, Griffiths CE, et al, “The Use of Folic Acid Supplementation in Psoriasis Patients Receiving Methotrexate: A Survey in the United Kingdom,” <i>Clin Exp Dermatol</i>, 2000, 25(4):265-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10971481\">[PubMed 10971481]</a></p>\n<p>4. Tiftikci A, Ozdemir A, Tarcin O, et al, “Influence of Serum Folic Acid Levels on Plasma Homocysteine Concentrations in Patients with Rheumatoid Arthritis,” <i>Rheumatol Int</i>, 2006, 26(3):191-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15645233\">[PubMed 15645233]</a></p>\n<p>5. Hornung N, Ellingsen T, Stengaard-Pedersen K, et al, “Folate, Homocysteine, and Cobalamin Status in Patients with Rheumatoid Arthritis Treated with Methotrexate, and the Effect of Low Dose Folic Acid Supplement,” <i>J Rheumatol</i>, 2004, 31(12):2374-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15570637\">[PubMed 15570637]</a></p>\n<p>6. Morgan SL, Baggott JE, Lee JY, et al, “Folic Acid Supplementation Prevents Deficient Blood Folate Levels and Hyperhomocysteinemia During Longterm, Low Dose Methotrexate Therapy for Rheumatoid Arthritis: Implications for Cardiovascular Disease Prevention,” <i>J Rheumatol</i>, 1998, 25(3):441-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9517760\">[PubMed 9517760]</a></p>\n<p>7. Hartman M, van Ede A, Severens JL, et al, “Economic Evaluation of Folate Supplementation During Methotrexate Treatment in Rheumatoid Arthritis,” <i>J Rheumatol</i>, 2004, 31(5):902-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15124248\">[PubMed 15124248]</a></p>\n<p>8. van Ede AE, Laan RF, Blom HJ, et al, “Homocysteine and Folate Status in Methotrexate-Treated Patients With Rheumatoid Arthritis,” <i>Rheumatology (Oxford)</i>, 2002, 41(6):658-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12048292\">[PubMed 12048292]</a></p>\n<p>9. Chladek J, Simkova M, Vaneckova J, “The Effect of Folic Acid Supplementation on the Pharmacokinetics and Pharmacodynamics of Oral Methotrexate During the Remission-Induction Period of Treatment for Moderate-to-Severe Plaque Psoriasis,” <i>Eur J Clin Pharmacol</i>, 2008, 64(4):347-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18163165\">[PubMed 18163165]</a></p>\n<p>10. Prescribing information. Trexall (methotrexate). Pomona, NY: Duramed Pharmaceuticals, Inc., October 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3844":"<p><b>Title</b> Sympathomimetics / Sympathomimetics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sympathomimetics may enhance the adverse/toxic effect of other Sympathomimetics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of sympathomimetics (eg, blood pressure, heart rate) during concomitant use. Risk would seem less with locally applied dosage forms (eg, ophthalmic drops, or as a vasoconstrictor in a combination local anesthetic). However, higher doses of these products could yield high enough systemic concentrations of the sympathomimetic to cause problems.</p>\n<div>\n <p><b>Sympathomimetics Interacting Members</b> Acebrophylline, Albuterol, Amezinium, Aminophylline, Amphetamine, Arformoterol, Armodafinil, Bambuterol, Benzphetamine, Bitter Orange, Caffeine, Cocaine (Topical), Dexmethylphenidate, Dextroamphetamine, Diethylpropion, DOBUTamine, DOPamine, Doxapram, Dyphylline, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Fenoterol, Formoterol, Indacaterol, Isometheptene, Isoproterenol, Kola Nut, Levalbuterol, Levonordefrin, Lisdexamfetamine, Metaproterenol, Metaraminol, Methamphetamine, Methylphenidate, Midodrine, Modafinil, Naphazoline (Nasal), Naphazoline (Ophthalmic), Norepinephrine, Olodaterol, Oxymetazoline (Nasal), Phendimetrazine, Phentermine, Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic), Phenylephrine (Topical), Pirbuterol, Propylhexedrine, Pseudoephedrine, Ritodrine, Salmeterol, Terbutaline, Theophylline, Tulobuterol, Vilanterol, Xylometazoline</p>\n</div> \n<p><b>Discussion</b> Concomitant administration of two or more sympathomimetic agents may increase the risk of related adverse effects, especially on the cardiovascular system (eg, increased blood pressure, tachycardia).<sup>1,2</sup> Monitor patients for additive sympathomimetic effects if combined.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Foradil (formoterol) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2001.</p>\n<p>2. ProAmatine (midodrine) [prescribing information]. Lexington, MA: Shire US Inc; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3845":"<p><b>Title</b> Heparin / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aspirin may enhance the anticoagulant effect of Heparin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Although aspirin and heparin are used concomitantly at times, the risk of bleeding appears to be increased and should be monitored accordingly.</p> \n<p><b>Discussion</b> The risk of bleeding during concomitant use of heparin and aspirin has been reported to be approximately 2.5-fold higher than in patients receiving heparin without aspirin.<sup>1</sup> Upper GI bleeding occurred in 28 of 138 coronary stent placement patients receiving heparin (followed by warfarin) anticoagulation and concomitant aspirin within a mean of 2.5 days of therapy initiation.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Walker A and Jick H, “Predictors of Bleeding During Heparin Therapy,” <i>JAMA</i>, 1980, 244:1209-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7411781\">[PubMed 7411781]</a></p>\n<p>2. Younossi ZM, Strum WB, Schatz RA, et al, “Effect of Combined Anticoagulation and Low-Dose Aspirin Treatment on Upper Gastrointestinal Bleeding,” <i>Dig Dis Sci</i>, 1997, 42(1):79-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9009119\">[PubMed 9009119]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3847":"<p><b>Title</b> Methadone / Interferons (Alfa)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Interferons (Alfa) may increase the serum concentration of Methadone. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for potentially enhanced effects of methadone with concurrent use of alfa interferons. Though this interaction is expected to be minimal for most patients, some substantial increases in methadone concentrations have been reported.</p>\n<div>\n <p><b>Interferons (Alfa) Interacting Members</b> Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Peginterferon Alfa-2a*, Peginterferon Alfa-2b*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Mean methadone AUC increased 16% in patients (n=18) previously stable on methadone who received pegylated interferon alfa-2b.<sup>1</sup> Of note, despite the minimal overall effect of this combination, methadone AUC approximately doubled in 2 patients. Other interaction studies have reported a similar minimal overall effect of pegylated interferon alfa-2b on methadone pharmacokinetics (AUC increases of only up to 16-19%; n=9 to 22).<sup>2,3,4</sup> However, none of these studies noted any outliers with substantially greater pharmacokinetic changes or with significant adverse effects. Similarly, methadone concentrations were only minimally increased (by 10-15%) after 4 weeks of concurrent pegylated interferon alfa-2a in a study of 24 patients with hepatitis C.<sup>5</sup> Though not specifically designed to evaluate the presence/absence of a pharmacokinetic drug interaction, several other studies have also reported the successful (and safe) concurrent use of pegylated interferon with methadone.<sup>6,7,8</sup><br><br>The precise mechanism for this potential interaction is uncertain, but interferons have been reported to alter hepatic drug metabolizing enzymes, suggesting that altered metabolism may be responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. PegIntron (peginterferon alfa-2b). Kenilworth, NJ: Schering-Plough Corporation, 8/09.</p>\n<p>2. Gupta SK, Sellers E, Somoza E, et al, “The Effect of Multiple Doses of Peginterferon Alfa-2b on the Steady-State Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy,” <i>J Clin Pharmacol</i>, 2007, 47(5):604-12. [PMID: 17400820]</p>\n<p>3. Berk SI, Litwin AH, Arnsten JH, et al, “Effects of Pegylated Interferon Alfa-2b on the Pharmacokinetic and Pharmacodynamic Properties of Methadone: a Prospective, Nonrandomized, Crossover Study in Patients Coinfected with Hepatitis C and HIV Receiving Methadone Maintenance Treatment,” <i>Clin Ther</i>, 2007, 29(1):131-8. [PMID: 17379053]</p>\n<p>4. Sulkowski M, Wright T, Rossi S, et al, “Peginterferon Alfa-2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy,” <i>Clin Pharmacol Ther</i>, 2005, 77(3):214-24. [PMID: 15735615]</p>\n<p>5. Prescribing information. Pegasys (peginterferon alfa-2a). Nutley, NJ: Hoffmann-La Roche Inc., August 2009.</p>\n<p>6. Litwin AH, Harris KA Jr, Nahvi S, et al, “Successful Treatment of Chronic Hepatitis C with Pegylated Interferon in Combination with Ribavirin in a Methadone Maintenance Treatment Program,” <i>J Subst Abuse Treat</i>, 2009, 37(1):32-40. [PMID: 19038524]</p>\n<p>7. Belfiori B, Ciliegi P, Chiodera A, et al, “Peginterferon Plus Ribavirin for Chronic Hepatitis C in Opiate Addicts on Methadone/Buprenorphine Maintenance Therapy,” <i>Dig Liver Dis</i>, 2009, 41(4):303-7. [PMID: 18938116]</p>\n<p>8. Bonkovsky HL, Tice AD, Yapp RG, et al, “Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration,” <i>Am J Gastroenterol</i>, 2008, 103(11):2757-65. [PMID: 18684176]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3852":"<p><b>Title</b> Vaccines (Inactivated) / Immunosuppressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated less than 14 days before starting immunosuppressive therapy or while receiving immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). Reduced efficacy of the vaccine (eg, reduced immune response) may occur if administered to patients on immunosuppressant therapy.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exception</b> Cytarabine (Liposomal)</p>\n <p><b>Vaccines (Inactivated) Interacting Members</b> Anthrax Vaccine Adsorbed, Diphtheria and Tetanus Toxoids, Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), Poliovirus (Inactivated), and Haemophilus influenzae B Conjugate (Adsorbed) Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine, Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), and Poliovirus (Inactivated) Vaccine, Haemophilus b Conjugate Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine (Recombinant [Adjuvanted]), Hepatitis B Vaccine (Recombinant), Influenza A Virus Vaccine (H5N1), Influenza Virus Vaccine (Inactivated), Japanese Encephalitis Virus Vaccine (Inactivated), Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine, Meningococcal Group B Vaccine, Meningococcal Group C-CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide (Groups C and Y) and Haemophilus b Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Group C Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine (Groups A / C / Y and W-135), Papillomavirus (9-Valent) Vaccine (Human, Recombinant), Papillomavirus (Types 16, 18) Vaccine (Human, Recombinant), Papillomavirus (Types 6, 11, 16, 18) Vaccine (Human, Recombinant), Pneumococcal Conjugate Vaccine (10-Valent), Pneumococcal Conjugate Vaccine (13-Valent), Pneumococcal Conjugate Vaccine (7-Valent), Pneumococcal Polysaccharide Vaccine (23-Valent), Poliovirus Vaccine (Inactivated), Q Fever Vaccine, Rabies Vaccine, Tetanus Toxoid (Adsorbed), Tick-Borne Encephalitis Virus Vaccine (Inactivated), Travelers' Diarrhea and Cholera Vaccine, Typhoid and Hepatitis A Vaccine, Zoster Vaccine (Recombinant)</p>\n</div> \n<p><b>Discussion</b> General recommendations of the Advisory Committee on Immunization Practices (ACIP) state that inactivated vaccines can be administered safely to persons with altered immunocompetence.<sup>1</sup> The usual doses and schedules are recommended, however, the effectiveness of such vaccinations might be suboptimal.<sup>1</sup> If possible, all age-appropriate vaccinations should be completed at least 2 weeks prior to initiation of an immunosuppressant. Patients vaccinated during or less than 14 days before starting immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). [published correction appears in <i>MMWR Recomm Rep</i>. 2011;60(29):993]<i>MMWR Recomm Rep</i>. 2011;60(2):1-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21293327\">[PubMed 21293327]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3853":"<p><b>Title</b> Corticosteroids (Ophthalmic) / Nonsteroidal Anti-Inflammatory Agents (Ophthalmic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for delayed or slow healing of ophthalmic tissue during concomitant use of corticosteroid and NSAID ophthalmic products.</p>\n<div>\n <p><b>Corticosteroids (Ophthalmic) Interacting Members</b> Betamethasone (Ophthalmic), Dexamethasone (Ophthalmic), Difluprednate, Fluocinolone (Ophthalmic), Fluorometholone, Hydrocortisone (Ophthalmic), Medrysone, PrednisoLONE (Ophthalmic), Rimexolone, Triamcinolone (Ophthalmic)<br><b>Exception</b> Loteprednol</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) Interacting Members</b> Bromfenac, Diclofenac (Ophthalmic), Flurbiprofen (Ophthalmic), Ketorolac (Ophthalmic), Nepafenac</p>\n</div> \n<p><b>Discussion</b> The concomitant use of ophthalmic corticosteroids and ophthalmic NSAIDs may negatively affect the healing process of ophthalmic tissue, as each class of medications has been associated with delayed wound healing. Product labeling for several ophthalmic NSAID products warns of this potential interaction.<sup>1,2,3,4</sup> Additionally, in a small retrospective study, concurrent ophthalmic corticosteroids use was reported to be a risk factor for ophthalmic NSAID-induced corneal erosion and perforation.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Xibrom</i> (bromfenac) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Inc; January 2014.</p>\n<p>2. <i>Ocufen</i> (flurbiprofen) [prescribing information]. Irvine, CA: Allergan Inc; June 2012. </p>\n<p>3. <i>Acular</i> (ketorolac) [prescribing information]. Irvine, CA: Allergan Inc; May 2012. </p>\n<p>4. <i>Ilevro</i> (nepafenac) [prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; December 2012.</p>\n<p>5. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. <i>Ophthalmology</i>. 2001;108(5):936-944. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11320025\">[PubMed 11320025]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3855":"<p><b>Title</b> Anticholinergic Agents / Pramlintide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pramlintide may enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced GI motility may occur.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> One of the actions of pramlintide is to slow gastric emptying. Therefore, the manufacturer recommends that patients receiving drugs that alter GI motility (eg, anticholinergics) not be considered for pramlintide therapy.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc, 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3857":"<p><b>Title</b> Imatinib / Lansoprazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lansoprazole may enhance the dermatologic adverse effect of Imatinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased severity of dermatologic adverse effects during concomitant use of lansoprazole and imatinib.</p> \n<p><b>Discussion</b> Case report. A patient with gastrointestinal stromal tumors developed edema, and then Stevens-Johnson syndrome, respectively, during consecutive treatment periods where she received both lansoprazole and imatinib.<sup>1</sup> The adverse events ceased in each instance following discontinuation of both agents. A mechanism for this apparent drug interaction is unknown. Either agent, alone, may have been responsible for the observed reactions. Their concomitant use may have resulted in additive effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Severino G, Chillotti C, De Lisa R, et al, “Adverse Reactions During Imatinib and Lansoprazole Treatment in Gastrointestinal Stromal Tumors,” <i>Ann Pharmacother</i>, 2005, 39(1):162-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15546944\">[PubMed 15546944]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3858":"<p><b>Title</b> NIFEdipine / Micafungin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Micafungin may increase the serum concentration of NIFEdipine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The nifedipine AUC and maximum serum concentration were increased by an average of 18% and 42%, respectively, in subjects receiving micafungin.<sup>1</sup> The mechanism of this increase is unclear; however, its clinical significance appears minimal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mycamine (micafungin) [prescribing information]. Deerfield, IL: Astellas Pharma US, Inc.; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3859":"<p><b>Title</b> Sirolimus / Micafungin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Micafungin may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor sirolimus response and serum concentrations closely if used together with micafungin.</p> \n<p><b>Discussion</b> The AUC of sirolimus was increased by an average of 21% in subjects receiving micafungin, but the average maximum serum concentration of sirolimus was not changed.<sup>1</sup> The mechanism of this increase is unclear, but may involve CYP3A4 inhibition by micafungin. The clinical significance of this interaction appears minimal, but caution and close monitoring of sirolimus is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mycamine (micafungin) [prescribing information]. Deerfield, IL: Astellas Pharma US, Inc.; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3861":"<p><b>Title</b> Bimatoprost / Latanoprost</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> The concomitant use of Latanoprost and Bimatoprost may result in increased intraocular pressure. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for paradoxical increases in intraocular pressure during concomitant use. Consider avoiding this combination of therapy when possible.</p> \n<p><b>Discussion</b> Concomitant therapy with bimatoprost and latanoprost results in inreased intraocular pressure in some patients being treated for primary open angle glaucoma.<sup>1,2</sup> The increase in one 18-patient study was 1.8 mmHg.<sup>1</sup> The mechanism of this paradoxical effect is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doi LM, Melo LA Jr, Prata JA Jr. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: A randomised clinical trial. <i>Br J Ophthalmol</i>. 2005;89(5):547-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15834081\">[PubMed 15834081]</a></p>\n<p>2. Herndon LW, Asrani SG, Williams GH, et al. Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. <i>Arch Ophthalmol</i>. 2002;120(6):847-849. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12049597\">[PubMed 12049597]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3862":"<p><b>Title</b> Dolasetron / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may decrease the metabolism of Dolasetron. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of hydrodolasetron (the active metabolite of dolasetron given as 200 mg daily) was increased 24% in 18 normal subjects when coadministered with cimetidine (300 mg four times daily) for 7 days.<sup>1</sup> Cimetidine likely inhibited the CYP3A4 enzyme-mediated metabolism of hydrodolasetron. The clinical implications of these changes appear minimal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dimmitt DC, Cramer MB, Keung A, et al, “Pharmacokinetics of Dolasetron with Coadministration of Cimetidine or Rifampin in Healthy Subjects,” <i>Cancer Chemother Pharmacol</i>, 1999, 3(2):126-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9923817\">[PubMed 9923817]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3864":"<p><b>Title</b> NIFEdipine / Cisapride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cisapride may increase the serum concentration of NIFEdipine. Reported with sustained release nifedipine product. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased (short-term) effects of nifedipine (sustained release) if coadministered with cisapride.</p> \n<p><b>Discussion</b> The clinical effects and serum concentrations of nifedipine (20 mg sustained release tablet) were significantly increased in 20 normal subjects receiving cisapride (2.5 mg) at 3 hours after nifedipine administration.<sup>1</sup> The effects were not noted at 1 hour after administration. Cisapride's effects on gastrointestinal motility likely enhanced the absorption rate of the nifedipine. The overall clinical effects are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Satoh C, Sakai T, Kashiwagi H, et al, “Influence of Cisapride on the Pharmacokinetics and Antihypertensive Effect of Sustained-Release Nifedipine,” <i>Intern Med</i>, 1996, 35(12):941-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9030991\">[PubMed 9030991]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3865":"<p><b>Title</b> VinCRIStine / NIFEdipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> NIFEdipine may increase the serum concentration of VinCRIStine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased vincristine toxicity in patients receiving nifedipine.</p> \n<p><b>Discussion</b> In a clinical study of patients with solid tumors, the AUC and terminal half-life of vincristine (2 mg) were approximately fourfold greater in 12 patients receiving nifedipine (10 mg 3 times daily beginning 3 days before vincristine and continuing for 7 days afterwards) compared to a control group not treated with nifedipine.<sup>1</sup> The volume of distribution was unchanged, and no untoward clinical effects were noted. A single published case report describes significant neurologic toxicity in a patient receiving vincristine, nifedipine, and itraconazole, although the role of nifedipine specifically in this case is uncertain as itraconazole is also strongly suspected to interact with vincristine.<sup>2</sup><br><br>The mechanism of this interaction is unclear. Nifedipine could theoretically increase systemic concentrations of vincristine via reducing its p-glycoprotein mediated efflux.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fedeli L, Colozza M, Boschetti E, et al, “Pharmacokinetics of Vincristine in Cancer Patients Treated with Nifedipine,” <i>Cancer</i>, 1989, 64(9):1805-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2790693\">[PubMed 2790693]</a></p>\n<p>2. Sathiapalan RK and El-Solh H, “Enhanced Vincristine Neurotoxicity From Drug Interactions: Case Report and Review of Literature,” <i>Pediatr Hematol Oncol</i>, 2001, 18(8):543-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11764105\">[PubMed 11764105]</a></p>\n<p>3. Ferry DR, Russell MA, and Cullen MH, “P-glycoprotein Possesses a 1,4-Dihydropyridine-Selective Drug Acceptor Site Which Is Alloserically Coupled to a Vinca-Alkaloid-Selective Binding Site,” <i>Biochem Biophys Res Commun</i>, 1992, 188(1):440-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1358068\">[PubMed 1358068]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3866":"<p><b>Title</b> NIFEdipine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may increase the serum concentration of NIFEdipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of nifedipine if coadministered with alcohol.</p> \n<p><b>Discussion</b> The AUC of nifedipine (20 mg) was increased 54% in 10 normal subjects when coadministered with alcohol (75 mL of 94%).<sup>1</sup> Alcohol likely inhibited the CYP3A4-mediated metabolism of nifedipine.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Qureshi S, Laganiere S, Caille G, et al, “Effect of an Acute Dose of Alcohol on the Pharmacokinetics of Oral Nifedipine in Humans,” <i>Pharm Res</i>, 1992, 9(5):683-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1608903\">[PubMed 1608903]</a></p>\n<p>2. Patki KC, Greenblatt DJ, and von Moltke LL, “Ethanol Inhibits in-vitro Metabolism of Nifedipine, Triazolam and Testosterone in Human Liver Microsomes,” <i>J Pharm Pharmacol</i>, 2004, 56(8):963-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15285839\">[PubMed 15285839]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3868":"<p><b>Title</b> Antipsychotic Agents / Acetylcholinesterase Inhibitors (Central)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Although these agents are commonly coadministered, it seems prudent to monitor for the development of extrapyramidal symptoms (eg, generalized rigidity, shuffling gait, facial grimacing) during concomitant use of antipsychotics and centrally acting acetylcholinesterase inhibitors.</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors (Central) Interacting Members</b> Donepezil*, Galantamine, Rivastigmine</p>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol*, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE*, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe the development of severe extrapyramidal symptoms (EPS) (eg, generalized rigidity, shuffling gait, facial grimacing) in elderly patients within a few days of initiating concomitant therapy with an antipsychotic (risperidone or haloperidol) and a centrally acting acetylcholinesterase inhibitor (donepezil or tacrine).<sup>1,2,3,4</sup> Symptoms resolved after discontinuing the antipsychotic agent, the acetylcholinesterase inhibitor, or both. In one case, an 80-year old patient experienced EPS during concomitant therapy with donepezil (5 mg daily) and risperidone (1 mg daily), but not donepezil (5 mg daily) and olanzapine (2.5 mg daily).<sup>1</sup> The different outcomes may have been due to relative differences in the dosing of the antipsychotics in this elderly patient - risperidone (1mg) being relatively high compared to olanzapine (2.5 mg). In another case, an 87-year old patient experienced no EPS while taking 5 mg of haloperidol, but did when taking more than 5 mg daily, or while taking 5 mg plus tacrine (10 mg four times daily).<sup>4</sup> Consistent with the known pharmacology of these drugs, the observed symptoms are presumably due to a relative acetylcholine/dopamine imbalance (ie, increased acetylcholine in the presence of dopamine receptor blockade) in the CNS.<sup>1,2</sup> However, the reason for the limited number of reports of this type of outcome during coadministration of the offending agents is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Liu HC, Lin SK, and Sung SM, “Extrapyramidal Side-Effect Due to Drug Combination of Risperidone and Donepezil,” <i>Psychiatry Clin Neurosci</i>, 2002, 56(4):479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12109969\">[PubMed 12109969]</a></p>\n<p>2. Magnuson TM, Keller BK, and Burke WJ, “Extrapyramidal Side Effects in a Patient Treated with Risperidone Plus Donepezil,” <i>Am J Psychiatry</i>, 1998, 155(10):1458-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9766783\">[PubMed 9766783]</a></p>\n<p>3. McSwain ML and Forman LM, “Severe Parkinsonian Symptom Development on Combination Treatment with Tacrine and Haloperidol,” <i>J Clin Psychopharmacol</i>, 1995, 15(4):284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7593712\">[PubMed 7593712]</a></p>\n<p>4. Maany I, “Adverse Interaction of Tacrine and Haloperidol,” <i>Am J Psychiatry</i>, 1996, 153(11):1504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8890692\">[PubMed 8890692]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3871":"<p><b>Title</b> Ramelteon / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Ramelteon. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> According to the ramelteon prescribing information, ramelteon should not be used together with fluvoxamine.</p> \n<p><b>Discussion</b> The AUC of ramelteon was increased approximately 190-fold and the maximum serum concentration (Cmax) was increased approximately 70-fold with concurrent fluvoxamine in a study where fluvoxamine 100 mg twice/day was administered for 3 days prior to a single dose of ralemteon (16 mg).<sup>1</sup><br><br>This interaction has been primarily attributed to inhibition of the CYP1A2-mediated metabolism of ramelteon by fluvoxamine, which is a strong inhibitor of CYP1A2.<sup>1</sup> Fluvoxamine inhibition of CYP2C19 and/or CYP3A4, which also may participate in ramelteon metabolism, has also been proposed as a possible contributing mechanism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rozerem (ramelteon) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; November 2010.</p>\n<p>2. Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. <i>Drug Metab Dispos</i>. 2010;38(8):1381-1391. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20478852\">[PubMed 20478852]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3873":"<p><b>Title</b> Ramelteon / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Ramelteon. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of ramelteon if used with fluconazole.</p> \n<p><b>Discussion</b> The AUC and maximum serum concentration of ramelteon (16 mg single dose) were both increased by approximately 150% when administered with fluconazole.<sup>1</sup> Similar increases in exposure to M-II (the active metabolite of ramelteon) were also reported.<br><br>CYP1A2 is the major isoenzyme involved in the metabolism of ramelteon, but CYP2C and CYP3A4 are also involved. Fluconazole is an inhibitor of both 2C9 and 3A4 isoenzymes and is likely the reason for the observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Rozerem</i> (ramelteon) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3875":"<p><b>Title</b> Quinolones / Sevelamer</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction only applies to orally administered quinolone antibiotics. No interaction is anticipated with intravenous administration.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sevelamer may decrease the absorption of Quinolones. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer oral quinolones at least 2 hours before or 6 hours after sevelamer administration.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n</div> \n<p><b>Discussion</b> The AUC of oral ciprofloxacin (750 mg single dose) was decreased 48% in 15 healthy subjects when coadministered with 7 sevelamer capsules (403 mg each).<sup>1,2,3</sup> This reduction mirrored the reductions associated with coadministration of 4 calcium acetate tablets (667 mg each) in the same study. Prescribing information for sevelamer recommends that ciprofloxacin be administered at least 2 hours prior to or 6 hours after sevelamer administration.<sup>2,3</sup><br><br>The binding of sevelamer to ciprofloxacin in the gastrointestinal tract, impairing its absorption, is the possible mechanism of this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. <i>Am J Kidney Dis</i>. 2003;42(6):1253-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14655198\">[PubMed 14655198]</a></p>\n<p>2. <i>Renvela</i> (sevelamer) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2014.</p>\n<p>3. <i>Renagel</i> (sevelamer) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3876":"<p><b>Title</b> Pimozide / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of pimozide with selective serotonin reuptake inhibitors (SSRIs) should be avoided. The prescribing information for all individual SSRIs lists concurrent pimozide as contraindicated.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram*, Dapoxetine, Escitalopram, FLUoxetine*, FluvoxaMINE*, PARoxetine*, Sertraline*, Vilazodone, Vortioxetine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> SSRIs have varying effects on pimozide. Fluvoxamine (and, fluoxetine and sertraline to lesser degrees) hold the potential to decrease pimozide metabolism via CYP1A2 (fluvoxamine and fluoxetine) or 3A4 (sertraline). In vitro evidence suggests that no significant CYP3A4-mediated pharmacokinetic interaction between these agents will occur.<sup>1</sup> The same study also suggests that paroxetine is not a pharmacokinetically interacting drug. However, the manufacturer of paroxetine describes a 2.5-fold increase in serum pimozide concentrations (2 mg x1) when coadministered with paroxetine (60 mg daily).<sup>2</sup> Similarly, the manufacturer of sertraline reports a 40% increase in pimozide (2 mg single dose) AUC when coadministered with sertraline (200 mg daily).<sup>3</sup> The AUC of pimozide (2 mg x1) was increased 37% in 15 healthy subjects when administered following a 3-week course of sertraline (up to 200 mg daily).<sup>4</sup> No prolongation of the QT interval of greater or equal to 15% was observed in any subject. The mechanism of these apparent pharmacokinetic interactions is unclear. According to data presented in pimozide prescribing information, administration of pimozide (2mg) to subjects pre-treated with 11 days of citalopram (40mg QD), mean QTc interval was increased 10 msec as compared to pimozide alone.<sup>5</sup> Additionally, SSRIs may have additive CNS depressant effects with pimozide, and fluoxetine may have additive QTc-prolonging effects with pimozide.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Desta Z, Soukhova N, and Flockhart DA, “In Vitro Inhibition of Pimozide N-dealkylation by Selective Serotonin Reuptake Inhibitors and Azithromycin,” <i>J Clin Psychopharmacol</i>, 2002, 22(2):162-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11910261\">[PubMed 11910261]</a></p>\n<p>2. Prescribing information. Paxil (paroxetine). Research Triangle Park, NC: GlaxoSmithKline, 2005.</p>\n<p>3. Prescribing information. Zoloft (sertraline). New York, NY: Pfizer, Inc, 2002.</p>\n<p>4. Alderman J, “Coadministration of Sertraline with Cisapride or Pimozide: An Open-Label, Nonrandomized Examination of Pharmacokinetics and Corrected QT Intervals in Healthy Adult Volunteers,” <i>Clin Ther</i>, 2005, 27(7):1050-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16154484\">[PubMed 16154484]</a></p>\n<p>5. Prescribing information. Orap (pimozide). Sellersville, PA: Teva Pharmaceuticals USA, 1/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3878":"<p><b>Title</b> Cyclophosphamide / Etanercept</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of etanercept and cyclophosphamide due to an increased risk of developing solid cancer.</p> \n<p><b>Discussion</b> A secondary finding in a study designed to evaluate the effectiveness of etanercept in addition to standard therapy in maintaining remission in Wegener granulomatosis was an increased risk of developing cancers during concomitant therapy with cyclophosphamide.<sup>1</sup> Six of the 89 patients in the treatment group developed solid cancers (adenocarcinoma of the colon [2 cases]; cholangiocarcinoma; renal cell carcinoma; breast carcinoma; liposarcoma) while zero patients in the control group developed solid cancers. A similar number of patients in each group was receiving cyclophosphamide.<sup>1</sup> In a long-term follow-up of those study participants (N = 153 patients [85% of the original study]), 13 additional patients developed solid cancers, 8 in the etanercept group and 5 in the placebo group.<sup>2</sup> When combining patients in all time periods who developed solid tumors, the occurrence remained significantly higher in the etanercept group compared with the placebo group (18% vs 7%; <i>P</i>=0.03). Of note, when only the post-trial period was examined, the difference in malignancy development was not different between groups (10% vs 7%; <i>P</i>=0.39).<sup>2</sup><br><br>Prescribing information for both cyclophosphamide and etanercept describe the increased risk of developing solid tumors when these agents are combined, and the etanercept prescribing information recommends avoiding the combination.<sup>3,4</sup><br><br>The mechanism of this interaction has not been fully investigated, but cyclophosphamide use has been linked to the development of malignancy, and it has been hypothesized that the use of tumor necrosis factor (TNF)-alpha inhibitors, such as etanercept, might interfere with the normal physiologic effects of TNF-alpha that control tumor growth.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. <i>N Engl J Med</i>. 2005;352(4):351-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15673801\">[PubMed 15673801]</a></p>\n<p>2. Silva F, Seo P, Schroeder DR, et al; Wegener’s Granulomatosis Etanercept Trial Research Group. Solid malignancies among etanercept-treated patients with granulomatosis with polyangitis (Wegener’s): long-term followup of a multicenter longitudinal cohort. <i>Arthritis Rheum</i>. 2011;63(8):2495-2503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21484770\">[PubMed 21484770]</a></p>\n<p>3. <i>Enbrel</i> (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corp; November 2013.</p>\n<p>4. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3883":"<p><b>Title</b> Warfarin / Tigecycline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tigecycline may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased warfarin effects (i.e., INR/PT, signs/symptoms of bleeding) if coadministered with tigecycline.</p> \n<p><b>Discussion</b> The AUC of R-warfarin and S-warfarin (25 mg single dose of racemic warfarin) were increased an average of 68% and 29%, respectively, in healthy subjects when coadministered with tigecycline (100 mg x 1, then 50 mg every 12 hours).<sup>1</sup> The average clearance of R- and S-warfarin were decreased by 40% and 23%, respectively. No significant changes in the pharmacdynamic effects (e.g., INR) of warfarin were noted.<br><br>The mechanism of this apparent interaction is unclear. According to tigecycline prescribing information, in vitro studies concluded that tigecycline was not an inhibitor of any of the 6 cytochrome P450 enzymes tested, including CYP2C9, CYP2C19, CYP1A2, or CYP3A4,<sup>1</sup> all of which are partially involved in the metabolism of R- and/or S-warfarin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tygacil (tigecycline). Philadelphia, PA: Wyeth Pharmaceuticals Inc., January 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3884":"<p><b>Title</b> Retinoic Acid Derivatives / Tigecycline</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tigecycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Due to the risk of developing pseudotumor cerebri, consider avoiding this combination of drugs. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, dysopia, headache).</p>\n<div>\n <p><b>Retinoic Acid Derivatives Interacting Members</b> Acitretin, Alitretinoin (Systemic), Alitretinoin (Topical), Bexarotene (Systemic), ISOtretinoin (Systemic), Tretinoin (Systemic)<br><b>Exceptions</b> Adapalene, Bexarotene (Topical), Tretinoin (Topical)</p>\n</div> \n<p><b>Discussion</b> Case reports describe the development of pseudotumor cerebri (benign intracranial hypertension characterized by dizziness, dysopia, and headache) in patients receiving retinoic acid derivatives (eg, isotretinoin, etretinate), a significant number of which were also receiving a tetracycline antibiotic.<sup>1,2</sup> The maker of isotretinoin states that concomitant therapy with a tetracycline should be avoided.<sup>1</sup> The mechanism of this interaction is unclear. Caution is warranted if a retinoic acid derivative is coadministered with tigecycline.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Accutane [package insert]. Nutley, NJ: Roche Pharmaceuticals, 2000.</p>\n<p>2. Viraben R, Matthieu C, and Fonton B, “Benign Intracranial Hypertension During Etretinate Therapy for Mycosis Fungoides,” <i>J Am Acad Dermatol</i>, 1985, 13:515-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4056125\">[PubMed 4056125]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3885":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Tigecycline</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Tigecycline may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Concerns generated by anecdotal reports have been refuted by more rigorous scientific and clinical data. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Anecdotal data indicate the possibility that tetracycline antibiotics might inhibit the efficacy of oral contraceptives. These are almost exclusively related to estrogen-containing products.<sup>1,2,3,4,5</sup> A longitudinal, uncontrolled study showed that the incidence of pregnancy in antibiotic/oral contraceptive-receiving patients (n=356) was not statistically different from the control group [no antibiotic] (n=263).<sup>6</sup> Two small studies failed to show any pharmacokinetic effects of tetracycline or doxycycline on ethinyl estradiol or norethindrone.<sup>7,8</sup> A paucity of epidemiologic data suggests that the incidence of pregnancy that occurs with concomitant antibiotic and hormonal contraception is no greater than the incidence during the use of hormonal contraception alone without concomitant antibiotics.<sup>9,10,11</sup> A thorough review of this topic was conducted by Archer et al.<sup>12</sup> They concluded that “available scientific and pharmacokinetic data do not support the hypothesis that antibiotics (with the exception of rifampin) lower the contraceptive efficacy of oral contraceptives.” A year 2000 Practice Bulletin of the American College of Obstetrics and Gynecology recommends the use of nonhormonal contraceptives only with the concomitant use of rifampin or griseofulvin.<sup>13</sup> A proposed (yet otherwise unproven) mechanism for this potential interaction is based on the antibiotic's ability to reduce gut bacteria which are important for hydrolysis of conjugated estrogen, which subsequently permits the reabsorption of the estrogen (ie, enterohepatic circulation is interrupted, resulting in lower serum concentrations of the estrogen). No supporting evidence is available. The manufacturer of tigecycline warns of potential contraceptive failure during concomitant use; however, evidence is lacking.<sup>14</sup> Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bacon JF and Shenfield GM, “Pregnancy Attributable to Interaction Between Tetracycline and Oral Contraceptives,” <i>Br Med J</i>, 1980, 1:293. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7357347\">[PubMed 7357347]</a></p>\n<p>2. Back DJ, Breckenridge AM, Crawford FE, et al, “Interindividual Variation and Drug Interactions With Hormonal Steroids,” <i>Drugs</i>, 1981, 21:46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7009137\">[PubMed 7009137]</a></p>\n<p>3. Back DJ, Grimmer FM, Orme ML, et al, “Evaluation of Committee on Safety of Medicines Yellow Card Reports on Oral Contraceptive-Drug Interactions With Anticonvulsants and Antibiotics,” <i>Br J Clin Pharmacol</i>, 1988, 25:527-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3408633\">[PubMed 3408633]</a></p>\n<p>4. London BM and Lookingbill DP, “Frequency of Pregnancy in Acne Patients Taking Oral Antibiotics and Oral Contraceptives,” <i>Arch Dermatol</i>, 1994, 130:392-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8129425\">[PubMed 8129425]</a></p>\n<p>5. Hughes BR and Cunliffe WJ, “Interactions Between the Oral Contraceptive Pill and Antibiotics,” <i>Br J Dermatol</i>, 1990, 122:717. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2141276\">[PubMed 2141276]</a></p>\n<p>6. Helms SE, Bredle DL, Zajic J, et al, “Oral Contraceptive Failure Rates and Oral Antibiotics,” <i>J Am Acad Dermatol</i>, 1997, 36:705-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9146531\">[PubMed 9146531]</a></p>\n<p>7. Murphy AA, Zacur HA, Charache P, et al, “The Effect of Tetracycline on Levels of Oral Contraceptives,” <i>Am J Obst Gynecol</i>, 1991, 164:28-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1986620\">[PubMed 1986620]</a></p>\n<p>8. Neely JL, Abate M, Swinker M, et al, “The Effect of Doxycycline on Serum Levels of Ethinyl Estradiol, Norethindrone, and Endogenous Progesterone,” <i>Obstet Gynecol</i>, 1991, 77:416-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1992409\">[PubMed 1992409]</a></p>\n<p>9. Sparrow MJ, “Pill Method Failures,” <i>N Z Med J</i>, 1987, 100:102-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3470667\">[PubMed 3470667]</a></p>\n<p>10. Back DJ, Grimmer SF, Orme ML, et al, “Evaluation of Committee on Safety of Medicines Yellow Card Reports on Oral Contraceptive-Drug Interactions With Anticonvulsants and Antibiotics,” <i>Br J Clin Pharmacol</i>, 1988, 25:527-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3408633\">[PubMed 3408633]</a></p>\n<p>11. Helms SE, Bredle DL, Zajic J, et al, “Oral Contraceptive Failure Rates and Oral Antibiotics,” <i>J Am Acad Dermatol</i>, 1997, 36:705-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9146531\">[PubMed 9146531]</a></p>\n<p>12. Archer JS and Archer DF, “Oral Contraceptive Efficacy and Antibiotic Interaction: A Myth Debunked,” <i>J Am Acad Dermatol</i>, 2002, 46:917-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12063491\">[PubMed 12063491]</a></p>\n<p>13. ACOG Practice Bulletin, The Use of Hormonal Contraception in Women With Coexisting Medical Conditions, July, 2000, The American College of Obstetricians and Gynecologists, Washington DC.</p>\n<p>14. Tygacil [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3886":"<p><b>Title</b> SulfaSALAzine / Etanercept</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Etanercept may enhance the neutropenic effect of SulfaSALAzine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a study conducted over 6 months of 254 patients with active rheumatoid arthritis, white blood cell (WBC) counts were significantly lower in patients who received the combination of sulfasalazine and etanercept compared with those who received either drug alone.<sup>1</sup> However, the majority of WBC counts were still within normal limits and the incidence of leukopenia was similar between all three groups.<sup>1</sup> This study was then continued for 2 years and similar results were seen.<sup>2</sup> Patients who received the combination had a significantly greater reduction in WBC count compared with those receiving sulfasalazine alone, but the incidence of leukopenia was similar between groups.<sup>2</sup> In both analyses, no patients withdrew due to leukopenia and WBC counts normalized during the study.<sup>1,2</sup> In a separate safety study of 50 patients with active rheumatoid arthritis, the combination of sulfasalazine and etanercept was well-tolerated and no decreases in WBC count or leukopenia were reported.<sup>3</sup> <br><br>Etanercept prescribing information states that a mild decrease in neutrophil counts was seen with the combination compared to either therapy alone in a study where etanercept was initiated in patients taking sulfasalazine, but the clinical significance of this finding is unknown.<sup>4</sup><br><br>The likely mechanism of this interaction is that both drugs can independently cause neutropenia and their effects may be additive.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Combe B, Codreanu C, Fiocco U, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double blind comparison. <i>Ann Rheum Dis</i>. 2006;65(10):1357-1362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16606651\">[PubMed 16606651]</a></p>\n<p>2. Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomized 2 year study. <i>Ann Rheum Dis</i> 2009;68(7):1146-1152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18794178\">[PubMed 18794178]</a></p>\n<p>3. O’Dell JR, Petersen K, Leff R, et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. <i>J Rheumatol</i>. 2006;33(2):213-218. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16358366\">[PubMed 16358366]</a></p>\n<p>4. <i>Enbrel</i> (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation; November 2013.</p>\n<p>5. <i>Azulfidine</i> (sulfasalazine) [prescribing information]. New York, NY: Pfizer Inc; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3887":"<p><b>Title</b> RisperiDONE / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Verapamil may increase the serum concentration of RisperiDONE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicity of risperidone (eg, extrapyramidal symptoms) if verapamil is initiated/dose increased, and decreased effects if verapamil is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in12 healthy volunteers, the AUC and peak plasma concentration of risperidone (1 mg single dose) increased 2-fold and 1.8-fold, respectively, when coadministered with verapamil (240 mg daily for 6 days).<sup>1</sup><br><br>The mechanism of this interaction is likely verapamil mediated inhibition of P-glycoprotein and CYP3A4, a transporter and enzyme responsible for a portion of risperidone metabolism and disposition.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. <i>Clin Pharmacol Ther</i>. 2005;78(1):43-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16003291\">[PubMed 16003291]</a></p>\n<p>2. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 1999;359(2):147-151. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10048600\">[PubMed 10048600]</a></p>\n<p>3. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. <i>Life Sci</i>. 2002;71(2):163-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12031686\">[PubMed 12031686]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3889":"<p><b>Title</b> Typhoid Vaccine / Antibiotics</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only the live typhoid vaccine (oral product) is subject to this potential interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents, and when possible, antibacterials should not be started within 3 days of the last vaccine dose.</p>\n<div>\n <p><b>Antibiotics Interacting Members</b> Amdinocillin, Amikacin, Amoxicillin, Ampicillin, Arbekacin, Azithromycin (Systemic), Aztreonam (Systemic), Bacampicillin, Bedaquiline, Cefaclor, Cefadroxil, Cefazedone, CeFAZolin, Cefcapene, Cefdinir, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime, CefoTEtan, Cefotiam, CefOXitin, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone, Cefuroxime, Cephalexin, Cephalothin, Cephradine, Chloramphenicol (Ophthalmic), Chloramphenicol (Otic), Chloramphenicol (Systemic), Ciprofloxacin (Systemic), Clarithromycin, Clindamycin (Systemic), Clofazimine, Cloxacillin, Colistimethate, CycloSERINE, Dalbavancin, Dapsone (Systemic), Delafloxacin, Delamanid, Demeclocycline, Dicloxacillin, Doripenem, Doxycycline, Ertapenem, Erythromycin (Systemic), Ethambutol, Ethionamide, Flomoxef, Flucloxacillin, Fosfomycin, Fusidic Acid (Systemic), Gemifloxacin, Gentamicin (Systemic), Imipenem, Isepamicin, Isoniazid, Ivermectin (Systemic), Kanamycin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lincomycin, Linezolid, Lomefloxacin, Lymecycline, Meropenem, Methenamine, MetroNIDAZOLE (Systemic), Minocycline, Moxifloxacin (Systemic), Nafcillin, Nalidixic Acid, Nifuroxazide, Nitrofurantoin, Norfloxacin, Ofloxacin (Systemic), Oritavancin, Oxacillin, Oxytetracycline, Pefloxacin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Pentamidine (Oral Inhalation), Pentamidine (Systemic), Pipemidic Acid, Piperacillin, Prothionamide, Pyrazinamide, Rifabutin, RifAMPin, Rifapentine, Roxithromycin, Secnidazole, Sparfloxacin, Spiramycin, Streptomycin, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Tedizolid, Teicoplanin, Telavancin, Telithromycin, Temocillin, Tetracycline (Systemic), Ticarcillin, Tinidazole, Tobramycin (Systemic), Trimethoprim, Vancomycin<br><b>Exceptions</b> Acetic Acid (Otic), Acetic Acid (Topical), Aluminum Acetate, Azithromycin (Ophthalmic), Aztreonam (Oral Inhalation), Bacitracin (Ophthalmic), Bacitracin (Systemic), Bacitracin (Topical), Benzoin, Capreomycin, Chlortetracycline, Ciprofloxacin (Ophthalmic), Clindamycin (Topical), Dapsone (Topical), Dibrompropamidine (Ophthalmic), Dibrompropamidine (Topical), Erythromycin (Ophthalmic), Erythromycin (Topical), Fidaxomicin, Framycetin, Fusidic Acid (Ophthalmic), Fusidic Acid (Topical), Gatifloxacin, Gentamicin (Ophthalmic), Gentamicin (Topical), Gentian Violet, Hexachlorophene, Mafenide, MetroNIDAZOLE (Topical), Mupirocin, Neomycin, Nitrofurazone, Oxychlorosene, Ozenoxacin, Polymyxin B, Povidone-Iodine (Topical), RifAXIMin, Silver Nitrate, Silver Sulfadiazine, Sulfacetamide (Ophthalmic), Sulfacetamide (Topical), Taurolidine, Tobramycin (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> The prescribing information for the live attenuated typhoid vaccine (Ty21a) warns that it should not be administered to individuals who are being treated with antibacterial agents.<sup>1</sup> A report from the Advisory Committee on Immunization Practices (ACIP) advises that use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents, and when possible, antibacterials should not be started within 3 days of the last vaccine dose.<sup>2</sup> These recommendations are consistent with the concern regarding the potential for some antibacterial agents to interfere with the replication of and resultant immune response to the live bacterial strain used in the live vaccine.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Vivotif</i> (typhoid vaccine live oral Ty21a) [prescribing information]. Miami Lakes, FL: Crucell Vaccines Inc.; September 2013.</p>\n<p>2. Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine - advisory committee on immunization practices, United States, 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(11):305-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25811680\">[PubMed 25811680]</a></p>\n<p>3. Wolfe MS. Precautions with oral live typhoid (Ty 21a) vaccine. <i>Lancet</i>. 1990;336(8715):631-632. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1975401\">[PubMed 1975401]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3890":"<p><b>Title</b> Typhoid Vaccine / Mefloquine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mefloquine may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain would possibly be affected. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action needed.</p> \n<p><b>Discussion</b> In vitro data show that mefloquine can inhibit the growth of the live Ty21a strain, leading to some recommendations that if this antimalarial is administered, vaccination with Ty21a should be delayed for 24 hours.<sup>1,2,3,4</sup> In contrast, a study described in the oral typhoid vaccine prescribing information found that concurrent administration of the oral typhoid vaccine with mefloquine (250 mg weekly, n=30) was associated with a similar humoral IgG and IgA anti-<i>Salmonella typhi</i> response as individuals receiving the oral vaccine without mefloquine (n=45).<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Anonymous, “Typhoid Immunization Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR Morb Mortal Wkly Rep</i>, 1994, 43(RR14);1-7.</p>\n<p>2. Brachman PS, Metchock B, and Kozarsky PE, “Effects of Antimalarial Chemoprophylactic Agents on the Viability of the Ty21a Typhoid Vaccine Strain,” <i>Clin Infect Dis</i>, 1992, 15:1057-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1457647\">[PubMed 1457647]</a></p>\n<p>3. Horowitz H and Carbonaro CA, “Inhibition of the Salmonella-typhi Oral Vaccine Strain, Ty21a, by Mefloquine and Chloroquine,” <i>J Infect Dis</i>, 1992, 166:1462-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1431270\">[PubMed 1431270]</a></p>\n<p>4. Wolfe MS, “Precautions with Oral Live Typhoid (Ty 21a) Vaccine,” <i>Lancet</i>, 1990, 336:631-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1975401\">[PubMed 1975401]</a></p>\n<p>5. Prescribing information. Vivotif (Typhoid vaccine live oral Ty21a). Coral Gables, FL: Berna Products, August 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3891":"<p><b>Title</b> Thiazolidinediones / Pregabalin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pregabalin may enhance the fluid-retaining effect of Thiazolidinediones. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of weight gain and/or peripheral edema in patients receiving concomitant therapy with pregabalin and a thiazolidinedione derivative. Use caution in patients at increased risk of negative sequelae from such adverse events (eg, congestive heart failure).</p>\n<div>\n <p><b>Thiazolidinediones Interacting Members</b> Lobeglitazone, Pioglitazone*, Rosiglitazone*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Increased frequencies of weight gain and peripheral edema were noted in patients receiving pregabalin and a thiazolidinedione (eg, pioglitazone, rosiglitazone), compared to those receiving either drug alone, during clinical trials.<sup>1</sup> The effects of the individual agents appear to be additive.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lyrica [package insert]. New York, NY: Parke-Davis, 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3892":"<p><b>Title</b> Varicella Virus-Containing Vaccines / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid administration of salicylates for at least 6 weeks after adminstration of a varicella virus-containing vaccine.<sup>1,2</sup></p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p><b>Varicella Virus-Containing Vaccines Interacting Members</b> Measles, Mumps, Rubella, and Varicella Virus Vaccine*, Varicella Virus Vaccine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Reye's Syndrome is a known complication of salicylate ingestion in patients with acute viral infections (eg, varicella). Whether a similar association exists between salicylate administration and varicella virus vaccination is unknown.<sup>3</sup> Avoiding concomitant administration of these products is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. ProQuad [package insert]. Whitehouse Station, NJ: Merck &amp; Co, Inc, 2005.</p>\n<p>2. Varivax [package insert]. Whitehouse Station, NJ: Merck &amp; Co, Inc, 2003.</p>\n<p>3. Red Book: 2003 Report of the Committee on Infectious Diseases, Pickering LK, ed. 26th ed, American Academy of Pediatrics, Elk Grove Village, IL, 2003:686.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3893":"<p><b>Title</b> Metoprolol / Telithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Telithromycin may increase the serum concentration of Metoprolol. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the telithromycin prescribing information, telithromycin increased the metoprolol maximum serum concentration and AUC approximately 38%.<sup>1</sup><br><br>The mechanism of this interaction is likely due to telithromycin-mediated inhibition of CYP2D6, an enzyme responsible for metoprolol metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3894":"<p><b>Title</b> Vitamin K Antagonists / Tamoxifen</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: This combination is not specifically contraindicated in some non-U.S. labels.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tamoxifen may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Combined use of tamoxifen with warfarin is contraindicated in U.S. labeling due to risk of excessive anticoagulant response and resultant increased risk of bleeding. It is expected that tamoxifen would interact with other coumarin derivatives in a similar manner. Of note, this combination is not specifically contraindicated in some non-U.S. labeling.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Increased anticoagulant response to warfarin and/or clinically significant bleeding episodes with the combination of tamoxifen and warfarin have been described in various case reports and case series.<sup>1,2,3,4</sup> While warfarin was discontinued in some cases, in those in which the combination was continued, significant reductions in warfarin dose requirements (of approximately 35-60%) were noted. In a review of 31 patients receiving this combination, 8 patients experienced documented bleeding complications.<sup>5</sup><br><br>Due to the severity of the interaction, U.S. labeling for tamoxifen contraindicates the use of tamoxifen in women who require concomitant coumarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus.<sup>6,7</sup> In at least some international labels, however, including those from Canada and the UK, the combination is not listed as a contraindication, though it is noted that a significant increase in anticoagulant effect may occur when coumarin-type anticoagulants are used with tamoxifen.<sup>8,9,10</sup> If benefits outweigh risks of concomitant warfarin and tamoxifen therapy, anticoagulant dose adjustment will likely be necessary and anticoagulant status (i.e. PT/INR) and signs/symptoms of bleeding should be monitored closely.<br><br>Inhibition of warfarin metabolism by tamoxifen is likely the primary mechanism of this interaction. Tamoxifen has been shown to be a potent inhibitor of the CYP2C9 enzyme,<sup>11</sup> which accounts for most of the metabolism of S-warfarin (several-fold more potent anticoagulant effects vs. R-warfarin).<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lodwick R, McConkey B, Brown AM, “Life Threatening Interaction Between Tamoxifen and Warfarin,” <i>Br Med J</i>, 1987, 295:1141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3120919\">[PubMed 3120919]</a></p>\n<p>2. Tenni P, Lalich DL, Byrne MJ, “Life Threatening Interaction Between Tamoxifen and Warfarin,” <i>Br Med J</i>, 1989, 298:93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2493305\">[PubMed 2493305]</a></p>\n<p>3. Ritchie LD, Grant SMT, “Tamoxifen-Warfarin Interaction: the Aberdeen Hospitals Drug File,” <i>Br Med J</i>, 1989, 298:1253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2502242\">[PubMed 2502242]</a></p>\n<p>4. Mishra D, Paudel R, Kishore PV, et al, “Interaction between Warfarin and Tamoxifen: A Case Report,” <i>Kathmandu Univ Med J (KUMJ)</i>, 2007, 5(1):105-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18603996\">[PubMed 18603996]</a></p>\n<p>5. Givens CB, Bullock LN, Franks AS, “Safety of Concomitant Tamoxifen and Warfarin,” <i>Ann Pharmacother</i>, 2009, 43(11):1867-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19843839\">[PubMed 19843839]</a></p>\n<p>6. Prescribing information. Nolvadex (tamoxifen). Wilmington, DE: AstraZeneca Pharmaceuticals LP, 08-27-04.</p>\n<p>7. Product monograph. Soltamox (tamoxifen). East Brunswick, NJ: Savient Pharmaceuticals; October 2005.</p>\n<p>8. Product monograph. Apo-Tamox (tamoxifen). Toronto, ON, Canada: Apotex, Inc., January 2004.</p>\n<p>9. Product monograph. Nolvadex-D (tamoxifen). Mississauga, ON, Canada: Astrazeneca Canada, Inc., November 2012. </p>\n<p>10. Product monograph. Soltamox (tamoxifen). Leeds, Yorkshire, United Kingdom: Rosemont Pharmaceuticals Limited, March 2011.</p>\n<p>11. Boruban MC, Yasar U, Babaoglu MO, et al, “Tamoxifen Inhibits Cytochrome P450 2C9 Activity in Breast Cancer Patients,” <i>J Chemother</i>, 2006, 18(4):421-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17024799\">[PubMed 17024799]</a></p>\n<p>12. Kaminsky LS, Zhang ZY, “Human P450 Metabolism of Warfarin,” <i>Pharmacol Ther</i>, 1997, 73(1):67-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9014207\">[PubMed 9014207]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}